Resources

Stevenage Bioscience Catalyst Board appoints Andrew Waters as Chief Executive Officer

Tangram Therapeutics announces progression to patient cohorts in Phase 1/2 RESTORE-MASH trial of TGM-312 and appointment of Dr Sonya Montgomery as Chief Development Officer

Coulter Partners successfully led a search assignment for NRG Therapeutics Ltd. and is pleased to announce the placement of Claus Sundgreen, M.D. as Chief Medical Officer (CMO).

Foventa has strengthened its management team with a new CMO Dr Zaiba Malik and CFO Julia Jones as the company prepares for a Series A funding round to take lead asset FOV407 into a Phase IIb trial.

Imagine a world where diabetic patients no longer lose their sight. Foventa are already trialling a simple eyedrop that could make this a reality. Previously Exonate, Foventa are now Phase II ready and about to commence a Series A funding round.

Opening for participation on September 2nd 2026, PIR International’s 2027 EU/UK Biotech & Life Sciences Board Remuneration & Diversity Study will provide a comprehensive, data-driven view of board remuneration, composition and diversity across the European and UK life sciences sector.

Agilent Technologies has been announced as a founding member of Harwell’s new CO:LABS development.

Chris Molloy on Mike Hoare, the RedX-Skye deal, Stablepharma’s fridge-free vaccine, MHRA quarterly numbers, ministerial responsibilities for UK life sciences and human biology-based models

BIA Annual General Meeting 2026: nominations open for BIA Board election

The advantages to building a business in the UK's biotech clusters

Last month, the multi-award-winning Advanced Therapies Apprenticeship Community (ATAC) welcomed its 400th member. 

NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company developing novel disease-modifying therapeutics that rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce the appointment of Claus Sundgreen M.D. as chief medical officer (CMO), effective 1 August 2026.

ELRIG has appointed Drs Hitesh Sanganee and Marcus Schindler to its Scientific Advisory Board (SAB).

The Milner Therapeutics Institute has joined the o2h Discovery Platinum Partner Programme, enabling eligible companies within its bio-incubator and wider affiliate network to access specialist drug discovery support through the o2h Kickstarter Award.

Milner Institute convenes science, industry, investors and charity funders for Pitch Day and Symposium

Some of the UK's most promising student food innovators gathered at Colworth Science Park this month for the 2026 Ecotrophelia UK final, where seven university teams presented eco-innovative food concepts to a panel of industry judges.

Discover how BIA members influenced the UK Life Sciences Sector Jobs Plan, addressing critical biotech talent shortages, lab skills and AI innovation

Boyds, a leading global drug development consultancy, is pleased to announce the appointment of Laurence Skillern as Chief Medical Officer.

Coulter Partners successfully led a search for Salvia BioElectronics B.V. to place Jill Schiaparelli as Chair of its Board of Directors.

Key takeaways as another BIA Summer Party 2026 delivers for the life sciences sector